Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.38
NAS:SPPI's Cash-to-Debt is ranked lower than
77% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:SPPI: 1.38 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SPPI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.2  Med: 6.86 Max: 17918
Current: 1.38
0.2
17918
Equity-to-Asset 0.50
NAS:SPPI's Equity-to-Asset is ranked lower than
65% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:SPPI: 0.50 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SPPI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.2  Med: 0.57 Max: 0.95
Current: 0.5
0.2
0.95
Debt-to-Equity 0.50
NAS:SPPI's Debt-to-Equity is ranked lower than
64% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:SPPI: 0.50 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:SPPI' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.68  Med: 0.21 Max: 0.69
Current: 0.5
-0.68
0.69
Piotroski F-Score: 2
Altman Z-Score: 1.19
Beneish M-Score: -2.65
WACC vs ROIC
10.59%
-40.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -55.15
NAS:SPPI's Operating Margin % is ranked higher than
56% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:SPPI: -55.15 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SPPI' s Operating Margin % Range Over the Past 10 Years
Min: -484.81  Med: -33.57 Max: 30.17
Current: -55.15
-484.81
30.17
Net Margin % -59.33
NAS:SPPI's Net Margin % is ranked higher than
53% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:SPPI: -59.33 )
Ranked among companies with meaningful Net Margin % only.
NAS:SPPI' s Net Margin % Range Over the Past 10 Years
Min: -443.64  Med: -43.33 Max: 35.19
Current: -59.33
-443.64
35.19
ROE % -34.39
NAS:SPPI's ROE % is ranked higher than
51% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:SPPI: -34.39 )
Ranked among companies with meaningful ROE % only.
NAS:SPPI' s ROE % Range Over the Past 10 Years
Min: -72  Med: -23.84 Max: 39.19
Current: -34.39
-72
39.19
ROA % -18.60
NAS:SPPI's ROA % is ranked higher than
58% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:SPPI: -18.60 )
Ranked among companies with meaningful ROA % only.
NAS:SPPI' s ROA % Range Over the Past 10 Years
Min: -61.52  Med: -12.49 Max: 23.98
Current: -18.6
-61.52
23.98
ROC (Joel Greenblatt) % -7274.63
NAS:SPPI's ROC (Joel Greenblatt) % is ranked lower than
84% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:SPPI: -7274.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:SPPI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9016.53  Med: -1954.97 Max: 3089.46
Current: -7274.63
-9016.53
3089.46
3-Year Revenue Growth Rate -7.80
NAS:SPPI's 3-Year Revenue Growth Rate is ranked lower than
65% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:SPPI: -7.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:SPPI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -6.2 Max: 202.1
Current: -7.8
0
202.1
3-Year EBITDA Growth Rate 20.60
NAS:SPPI's 3-Year EBITDA Growth Rate is ranked higher than
73% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:SPPI: 20.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:SPPI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -70.9  Med: -17.5 Max: 108.9
Current: 20.6
-70.9
108.9
3-Year EPS without NRI Growth Rate -2.70
NAS:SPPI's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:SPPI: -2.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:SPPI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -70.1  Med: -15.8 Max: 128.1
Current: -2.7
-70.1
128.1
GuruFocus has detected 5 Warning Signs with Spectrum Pharmaceuticals Inc $NAS:SPPI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SPPI's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

SPPI Guru Trades in Q3 2016

Barrow, Hanley, Mewhinney & Strauss 238,988 sh (New)
Paul Tudor Jones 79,444 sh (+85.76%)
Jim Simons 5,541,957 sh (+21.58%)
Joel Greenblatt Sold Out
» More
Q4 2016

SPPI Guru Trades in Q4 2016

Paul Tudor Jones 86,378 sh (+8.73%)
Barrow, Hanley, Mewhinney & Strauss 238,988 sh (unchged)
Jim Simons 5,177,312 sh (-6.58%)
» More
Q1 2017

SPPI Guru Trades in Q1 2017

Jim Simons 5,679,800 sh (+9.71%)
Barrow, Hanley, Mewhinney & Strauss 231,745 sh (-3.03%)
Paul Tudor Jones 21,900 sh (-74.65%)
» More
Q2 2017

SPPI Guru Trades in Q2 2017

Jim Simons 6,071,817 sh (+6.90%)
Barrow, Hanley, Mewhinney & Strauss 231,745 sh (unchged)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:SPPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Barrow, Hanley, Mewhinney & Strauss 2017-03-31 Reduce -3.03%$4.46 - $6.73 $ 9.4569%231,745
Barrow, Hanley, Mewhinney & Strauss 2016-09-30 New Buy$4.47 - $7.1 $ 9.4560%238,988
Joel Greenblatt 2016-09-30 Sold Out $4.47 - $7.1 $ 9.4560%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ENTA, NAS:ITCI, NAS:KERX, NAS:BYSI, NAS:EDIT, NAS:RGNX, NAS:ZIOP, NAS:ADRO, NAS:TGTX, NAS:VNDA, NAS:NTLA, NAS:ANIK, NAS:AKBA, NAS:RETA, NAS:PTCT, NAS:AMRI, NAS:IMGN, NAS:ARNA, NAS:CYTK, NAS:RVNC » details
Traded in other countries:NTR.Germany,
Headquarter Location:USA
Spectrum Pharmaceuticals Inc is a biotechnology company in the United States. It develops drugs to cure serious diseases such as chemotherapy-induced neutropenia in patients with breast cancer.

Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. As an oncology products manufacturer, it develops drugs to combat various kinds of tumors. The SPI-2012 is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN addresses immediate intravesical instillation and post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. Its other products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA.

Ratios

vs
industry
vs
history
PB Ratio 3.83
SPPI's PB Ratio is ranked higher than
65% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. SPPI: 3.83 )
Ranked among companies with meaningful PB Ratio only.
SPPI' s PB Ratio Range Over the Past 10 Years
Min: 0.64  Med: 2.15 Max: 5.24
Current: 3.83
0.64
5.24
PS Ratio 5.69
SPPI's PS Ratio is ranked higher than
74% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. SPPI: 5.69 )
Ranked among companies with meaningful PS Ratio only.
SPPI' s PS Ratio Range Over the Past 10 Years
Min: 1.07  Med: 3.21 Max: 530.91
Current: 5.69
1.07
530.91
EV-to-EBIT -10.40
SPPI's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. SPPI: -10.40 )
Ranked among companies with meaningful EV-to-EBIT only.
SPPI' s EV-to-EBIT Range Over the Past 10 Years
Min: -25.8  Med: -3.4 Max: 63.5
Current: -10.4
-25.8
63.5
EV-to-EBITDA -16.92
SPPI's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. SPPI: -16.92 )
Ranked among companies with meaningful EV-to-EBITDA only.
SPPI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1739.5  Med: -2.4 Max: 84.8
Current: -16.92
-1739.5
84.8
EV-to-Revenue 5.72
SPPI's EV-to-Revenue is ranked higher than
76% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. SPPI: 5.72 )
Ranked among companies with meaningful EV-to-Revenue only.
SPPI' s EV-to-Revenue Range Over the Past 10 Years
Min: -1.1  Med: 2.7 Max: 387.6
Current: 5.72
-1.1
387.6
Current Ratio 3.08
SPPI's Current Ratio is ranked lower than
55% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. SPPI: 3.08 )
Ranked among companies with meaningful Current Ratio only.
SPPI' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.97 Max: 16.82
Current: 3.08
0.56
16.82
Quick Ratio 2.93
SPPI's Quick Ratio is ranked lower than
54% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. SPPI: 2.93 )
Ranked among companies with meaningful Quick Ratio only.
SPPI' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.87 Max: 16.8
Current: 2.93
0.56
16.8
Days Inventory 70.02
SPPI's Days Inventory is ranked higher than
74% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. SPPI: 70.02 )
Ranked among companies with meaningful Days Inventory only.
SPPI' s Days Inventory Range Over the Past 10 Years
Min: 65.64  Med: 98.78 Max: 281.63
Current: 70.02
65.64
281.63
Days Sales Outstanding 116.05
SPPI's Days Sales Outstanding is ranked lower than
74% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. SPPI: 116.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
SPPI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 9.09  Med: 101.41 Max: 138.24
Current: 116.05
9.09
138.24

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.90
SPPI's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. SPPI: -7.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SPPI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -149.9  Med: -23.85 Max: -3.6
Current: -7.9
-149.9
-3.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 315.00
SPPI's Price-to-Net-Current-Asset-Value is ranked lower than
94% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. SPPI: 315.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SPPI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.84  Med: 9.27 Max: 342.67
Current: 315
0.84
342.67
Price-to-Tangible-Book 25.54
SPPI's Price-to-Tangible-Book is ranked lower than
83% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. SPPI: 25.54 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SPPI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.66  Med: 6.14 Max: 581.43
Current: 25.54
0.66
581.43
Price-to-Intrinsic-Value-Projected-FCF 3.29
SPPI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
66% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. SPPI: 3.29 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SPPI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.09  Med: 1.66 Max: 12.11
Current: 3.29
1.09
12.11
Price-to-Median-PS-Value 1.77
SPPI's Price-to-Median-PS-Value is ranked lower than
72% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. SPPI: 1.77 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SPPI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 1.92 Max: 3541.67
Current: 1.77
0.18
3541.67
Earnings Yield (Greenblatt) % -9.59
SPPI's Earnings Yield (Greenblatt) % is ranked lower than
63% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. SPPI: -9.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SPPI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1825.9  Med: -11 Max: 1967.3
Current: -9.59
-1825.9
1967.3

More Statistics

Revenue (TTM) (Mil) $132.03
EPS (TTM) $ -0.98
Beta1.42
Short Percentage of Float14.32%
52-Week Range $3.21 - 10.77
Shares Outstanding (Mil)84.46

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 134 126 190 216
EPS ($) -0.57 -0.47 0.11 0.42
EPS without NRI ($) -0.57 -0.47 0.11 0.42
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:SPPI

Headlines

Articles On GuruFocus.com
Goodhaven Funds' First-Quarter Shareholder Letter May 17 2017 
AT&T Will Benefit From DirecTV Acquistion Aug 14 2015 
Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
5 Stocks Exceeding Expectations In 2012 Mar 31 2012 
Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Weekly CFO Buys Highlight: CNYD, PRWT, ANCB, SPPI, SPAX Jan 30 2011 
Weekly CFO Buys Highlight: FUL, SPPI, GRF, BPAX Jan 24 2011 
Weekly Top Insider Buys: NPBC, FUL, GAM, SHLM, SPPI Jan 23 2011 
Spectrum Pharmaceuticals Inc. (SPPI) CFO Brett L Scott buys 4,000 Shares Jan 21 2011 

More From Other Websites
Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September Sep 05 2017
Evomela’s Market Share Is Increasing in 2017 Sep 01 2017
ETFs with exposure to Spectrum Pharmaceuticals, Inc. : August 25, 2017 Aug 25 2017
Spectrum Pharmaceuticals to Present Corporate Update at the 2017 Southern California Investor... Aug 17 2017
Spectrum (SPPI) Initiates Phase II Study for Cancer Drug Aug 16 2017
Spectrum Pharmaceuticals, Inc. :SPPI-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16,... Aug 16 2017
Spectrum Pharmaceuticals Announces Initiation of the Registrational Phase 3 Trial of Qapzola™... Aug 14 2017
Edited Transcript of SPPI earnings conference call or presentation 3-Aug-17 8:30pm GMT Aug 11 2017
Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised Aug 08 2017
Spectrum Pharmaceuticals (SPPI) Looks Good: Stock Jumps 22.2% Aug 07 2017
Today's Research Reports on Stocks to Watch: Cara Therapeutics, Inc. and Spectrum Pharmaceuticals Aug 07 2017
Why Spectrum Pharmaceuticals Stock Is Bolting Higher Today Aug 04 2017
Spectrum (SPPI) Q2 Loss Narrower than Expected, Sales Beat Aug 04 2017
Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update Aug 03 2017
Investor Network: Spectrum Pharmaceuticals, Inc. to Host Earnings Call Aug 03 2017
Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study (ADVANCE)... Aug 01 2017
Spectrum Pharmaceuticals Announces Second Quarter 2017 Financial Results Teleconference and Webcast Jul 27 2017
Top 4 Small-Cap Stocks as of July 2017 Jul 12 2017
Top 4 Small-Cap Stocks for 2017 Jun 20 2017
Spectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN® (pralatrexate... Jun 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}